LBMI | |||||
---|---|---|---|---|---|
Variable | All patients(n=1857) | 11.7–17.6 (n=635) | 17.7–19.1 (n=621) | 19.2–23.6 (n=601) | p Value |
Age (years) | 70.6±10.9 | 74.2±10.2 | 70.8±9.8 | 66.0±11.1 | <0.001 |
Age ≥75 years | 718 (38.7) | 344 (54.2) | 233 (37.5) | 141 (23.5) | <0.001 |
Female | 436 (23.5) | 331 (52.1) | 99 (15.9) | 6 (0.9) | <0.001 |
BMI (kg/m2) | 23.8±3.6 | 20.6±2.3 | 23.7±2.2 | 27.1±2.7 | <0.001 |
BMI <18.5 kg/m2 | 97 (5.2) | 97 (15.2) | 0 (0) | 0 (0) | <0.001 |
BMI ≥30.0 kg/m2 | 91 (4.9) | 0 (0) | 12 (1.9) | 79 (13.1) | <0.001 |
FMI (kg/m2) | 5.4±2.2 | 4.3±1.7 | 5.3±2.1 | 6.8±1.9 | <0.001 |
Hypertension | 1347 (72.5) | 442 (69.6) | 429 (69.1) | 476 (79.2) | <0.001 |
Dyslipidaemia | 1107 (59.6) | 336 (52.9) | 355 (57.2) | 416 (69.2) | <0.001 |
LDL-C (mg/dL) | 108.1±35.4 | 105.5±35.9 | 106.9±32.1 | 112.0±37.7 | <0.001 |
HDL-C (mg/dL) | 47.9±13.8 | 51.3±14.9 | 47.4±13.2 | 45.0±12.6 | <0.001 |
Diabetes mellitus | 685 (36.9) | 198 (31.2) | 238 (38.3) | 249 (41.4) | 0.001 |
HbA1C (%) | 6.5±5.6 | 6.4±6.5 | 6.7±7.1 | 6.4±1.3 | 0.711 |
History of smoking | 948 (51.1) | 223 (35.1) | 326 (52.5) | 399 (66.4) | <0.001 |
eGFR (mL/min/1.73 m2) | 61.4±23.7 | 58.5±26.9 | 63.4±21.8 | 62.6±21.7 | <0.001 |
Haemodialysis | 112 (6.0) | 57 (8.9) | 25 (4.0) | 30 (4.9) | 0.001 |
Haemoglobin (g/dL) | 13.7±2.0 | 12.9±4.1 | 14.6±9.6 | 14.4±1.9 | <0.001 |
LVEF (%) | 60.2±13.4 | 59.2±14.3 | 61.2±13.1 | 60.3±12.6 | 0.056 |
LV dysfunction | 149 (8.0) | 65 (10.2) | 44 (7.1) | 40 (6.7) | 0.034 |
AF | 200 (10.8) | 81 (12.8) | 58 (9.3) | 61 (10.1) | 0.126 |
Medical history | |||||
Stroke | 181 (9.7) | 84 (13.2) | 49 (7.9) | 48 (7.9) | 0.001 |
PAD | 198 (10.7) | 97 (15.3) | 59 (9.5) | 42 (6.9) | <0.001 |
History of MI | 465 (25.0) | 138 (21.7) | 159 (25.6) | 168 (27.9) | 0.038 |
ACS on admission | 816 (43.9) | 309 (48.2) | 259 (41.7) | 248 (4.13) | 0.014 |
De novo lesion | 1648 (87.1) | 577 (90.9) | 551 (88.7) | 520 (86.5) | 0.053 |
ISR of DES | 83 (4.5) | 21 (3.3) | 26 (4.2) | 36 (5.9) | 0.067 |
ISR of BMS | 122 (6.6) | 40 (6.3) | 39 (6.3) | 43 (7.2) | 0.770 |
Lesion distribution | |||||
LAD | 871 (46.9) | 293 (46.2) | 296 (47.7) | 282 (46.9) | 0.864 |
LCX | 351 (18.9) | 121 (19.1) | 106 (17.1) | 124 (20.6) | 0.280 |
RCA | 686 (36.9) | 231 (36.9) | 235 (37.8) | 220 (36.6) | 0.847 |
LMT | 43 (2.4) | 21 (3.3) | 8 (1.3) | 14 (2.3) | 0.059 |
Bypass graft | 22 (1.2) | 10 (1.6) | 8 (1.3) | 4 (0.7) | 0.322 |
Multivessel disease | 727 (39.1) | 257 (40.4) | 249 (40.1) | 221 (36.8) | 0.338 |
Procedure success | 1719 (92.6) | 592 (93.2) | 578 (93.1) | 549 (91.3) | 0.380 |
Medications | |||||
Aspirin | 1771 (95.4) | 597 (94.0) | 596 (95.9) | 578 (96.2) | 0.728 |
Thienopyridines | 1638 (88.2) | 546 (85.9) | 554 (89.2) | 538 (89.5) | 0.365 |
Statins | 1305 (70.3) | 416 (65.5) | 424 (68.3) | 465 (77.4) | <0.001 |
ACE-I | 569 (30.6) | 195 (30.7) | 189 (30.4) | 185 (30.8) | 0.967 |
ARB | 673 (36.2) | 207 (32.6) | 200 (32.2) | 266 (44.3) | <0.001 |
β-blockers | 673 (36.2) | 236 (37.2) | 262 (42.2) | 255 (42.4) | 0.157 |
Warfarin | 165 (8.9) | 72 (11.3) | 67 (10.8) | 66 (10.9) | 0.917 |
Data are shown as mean±SD or n (%).
ACE-I, angiotensin converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; BMS, bare metal stent; CVD, cerebral vascular disease; DES, drug eluting stent; eGFR, estimated glomerular filtration rate; FMI, fat mass index; HbA1C, glycated haemoglobin; HDL-C, high density lipoprotein cholesterol; ISR, in-stent restenosis; LAD, left anterior descending artery; LBMI, lean body mass index; LCX, left circumflex artery; LDL-C, low density lipoprotein cholesterol; LMT, left main trunk; LV, left ventricular; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; RCA, right coronary artery.